Chronic endemic hydroarsenicism

Abstract

Chronic endemic hydroarsenicism in a 48-year-old man from Antofagasta, Chile, is reported. The literature on the global health problems of hydroarsenicism is reviewed, especially with regard to the carcinogenic action of arsenic.

Risk and protective factors for sporadic basal cell carcinoma: results of a two-centre case-control study in southern Germany. Clinical actinic elastosis may be a protective factor

“…Our data also showed such an association. Although it is widely accepted as a risk factor, 32,33 we did not find in our study that subjects who underwent arsenic therapy were at high risk for sporadic BCC. This might be because only four cases and one control had a positive history of arsenic therapy.…”

Noninfectious dermatological diseases associated with chronic exposure to mine tailings in a Peruvian district

“…32 The clinical manifestations of arsenicosis in the skin showed a high prevalence (9AE1 cases per 100 inhabitants). [33][34][35][36][37] This Table 2 Characteristics of the adult and paediatric populations, exposed and not exposed to mine tailings 37 Also, our results are similar to those reported by Guha et al, 13 Kadono et al 8 and other authors who found that the most frequent cutaneous manifestation of chronic endemic hydroarsenicosis was keratosis, affecting more males [33][34][35][36][37] than females. Although the toxicity produced by mine tailings is commonly acquired through drinking water, our study found that the most common routes for arsenic poisoning are inhalatory and percutaneous.…”

“…The clinical manifestations of arsenicosis in the skin showed a high prevalence (9·1 cases per 100 inhabitants) 33–37 . This value is similar to that reported by Guha et al.…”

“…, 13 Kadono et al. 8 and other authors who found that the most frequent cutaneous manifestation of chronic endemic hydroarsenicosis was keratosis, affecting more males 33–37 than females. Although the toxicity produced by mine tailings is commonly acquired through drinking water, our study found that the most common routes for arsenic poisoning are inhalatory and percutaneous.…”

Cutaneous manifestations and treatment of arsenic toxicity: A systematic review

“…also reported that sodium dimercaptosulfonate, a less toxic BAL salt, given as two courses of 0.25 mg oral daily for 3 days each can improve pruritus and arsenic‐induced keratoses 34 . Other case reports noted the use of 5%–10% salicylic acids in reducing hyperkeratosis suspected to be caused by chronic arsenic exposure 27,48,49 . Five case reports suggested that in presentations where there may be hyperkeratosis with concurrent cutaneous malignancies, individuals may respond well with oral retinoids such as acitretin, dose ranged 10–25 mg/day, in combination with other management strategies 23,27,47,50,51 …”